Table 2.
Approach | Vaccine Name | Vaccine Class | Manufacturer | Efficacy | Dosing and Storage |
---|---|---|---|---|---|
mRNA vaccine |
mRNA- 1273 |
Encapsulated mRNA | Moderna/NIAID | 94.1% against original strain | 2 doses- 4 weeks apart Stored at −20 °C |
BNT162b2 | Encapsulated mRNA | BioNTech/Pfizer/Fosun Pharma | 95% against original strain | 2 doses- 3 weeks apart Stored at −70 °C |
|
Replication of defective viral-vector vaccine |
Ad5-nCoV | Viral vector | CanSino Biological in collaboration with Beijing Institute of Biotechnology and Academy of Military Medical Sciences | Phase III (ongoing) | 1 dose- Stored at 2–8 °C |
ChAdOx1 /AZD1222 |
Viral vector | Oxford University/AstraZeneca | 70.4% against original strain | 2 doses- 4 weeks apart Stored at 2–8 °C |
|
Sputnik-V /Gam-COVID-Vac |
Viral vector | Acellena Contract Drug Research and Development in collaboration with Gamaleya Research Institute and Health Ministry of the Russian Federation | 91.4% against original strain | 2 doses- 3 weeks apart Stored at 2–8 °C |
|
JNJ-78436735/ Ad26.COV2.S |
Viral vector | Johnson & Johnson | 72% against original strain | 1 dose- Stored at 2–8 °C |
|
Inactivated vaccine |
CoronaVac “ Sinovac” |
Inactivated virus | Sinovac Research and Development Co. | 50% against original strain | 2 doses- 2 weeks apart Stored at 2–8 °C |
BBIBP-CorV | Inactivated virus | Beijing Institute of Biotechnology | 79.34% against original strain | 2 doses- 3 weeks apart Stored at 2–8 °C |
|
Sinopharm (Wuhan) |
Inactivated virus | China National Pharmaceutical Group (Sinopharm) in collaboration with Wuhan Institute of Biological Products | undisclosed | 2 doses- 3 weeks apart Stored at 2–8 °C |
|
BBV152/ Covaxin |
Inactivated virus | Bharat Biotech | 81% against original strain | 2 doses- 4 weeks apart Stored at 2–8 °C |
|
Subunit vaccine |
NVX- CoV2373 |
Recombinant spike (rS) and Matrix-M1 proteins |
Novavax | 96% against original strain | 2 doses- 3 weeks apart Stored at 2–8 °C |
ZF2001 | The repeated dimeric form of RBD of the SARS-CoV-2 S protein | Anhui Zhifei Longcom/ Chinese Academy of Medicine |
92–97% | 3 doses- 4 weeks apart Stored at 2–8 °C |
|
Virus-like particle (VLP) |
CoVLP (NCT04450004) | plant-produced VLP vaccine candidate expressing SARS-CoV-2 spike protein | Medicago/GlaxoSmithKline | Phase II–III clinical trial (ongoing) | 2 doses- 3 weeks apart Stored at 2–8 °C |